Skip to main content
. 2018 Oct 12;33(4):969–980. doi: 10.1038/s41375-018-0276-9

Table 4.

Incidence of TEAEs of interest by time to new onset for ibrutinib+BR-treated patients

TEAE, n (%) 0–1 year (n = 287) 1–2 years (n = 216) 2–3 years (n = 188)  > 3 years (n = 83)
Infection 190 (66.2) 22 (10.2) 4 (2.1) 1 (1.2)
Neutropenia 164 (57.1) 3 (1.4) 0 0
Nausea 105 (36.6) 1 (0.5) 0 0
Diarrhea 98 (34.1) 9 (4.2) 1 (0.5) 2 (2.4)
Thrombocytopenia 86 (30.0) 2 (0.9) 1 (0.5) 0
Bleeding 84 (29.3) 10 (4.6) 4 (2.1) 1 (1.2)
Pyrexia 69 (24.0) 5 (2.3) 4 (2.1) 0
Anemia 64 (22.3) 2 (0.9) 2 (1.1) 0
Fatigue 58 (20.2) 5 (2.3) 3 (1.6) 1 (1.2)
Cough 48 (16.7) 12 (5.6) 4 (2.1) 1 (1.2)
Pneumonia 38 (13.2) 15 (6.9) 7 (3.7) 1 (1.2)
Upper respiratory tract infection 38 (13.2) 17 (7.9) 4 (2.1) 2 (2.4)
Hypertension 27 (9.4) 8 (3.7) 4 (2.1) 0
Atrial fibrillation/flutter 19 (6.6) 4 (1.9) 6 (3.2) 0

TEAE treatment-emergent adverse event